Research in regenerative medicine is developing at a significantly quick pace. Cell-based bone and cartilage replacement is an evolving therapy aiming at the treatment of patients who suffer from limb amputation, damaged tissues and various bone and cartilage-related disorders. Stem cells are undifferentiated cells with the capability to regenerate into one or more committed cell lineages. Stem cells isolated from multiple sources have been finding widespread use to advance the field of tissue repair. The present review gives a comprehensive overview of the developments in stem cells originating from different tissues and suggests future prospects for functional bone and cartilage tissue regeneration.
Introduction to bone and regenerative capacity
Bones are characterized by patterns of microstructural organization which govern the mechanical interaction of the elementary components of bone (hydroxyapatite, collagen, water) and provide effective elastic properties. At a scale of 10 nm, long cylindrical collagen molecules, attached to each other at their ends by ∼1.5 nm long crosslinks and hosting intermolecular water in between, form a contiguous matrix called wet collagen. At a scale of several hundred nanometers, wet collagen and mineral crystal agglomerations interpenetrate each other, forming the mineralized fibril. At a scale of 5-10 µm, the extracellular solid bone matrix is represented as collagen fibril inclusions embedded in a foam of largely disordered (extrafibrillar) mineral crystals. At a scale above the ultrastructure, where lacunae are embedded in extracellular bone matrix, the extravascular bone material *Correspondence to: M. K. El Tamer, American University of Beirut, PO Box 11-0236, Abuhaidar Neuroscience Institute, Faculty of Medicine and Medical Center, Riad El-Solh, Beirut 1107 2020, Lebanon. E-mail: mazen.eltamer@aub.edu.lb is observed (Fritsch and Hellmich, 2007) . Human femoral trabecular bone has an apparent density and an apparent ash density of 0.43 g/cm 3 and 0.26 g/cm 3 , respectively. The human vertebral body has an apparent density of 0.14 ± 0.06 g/cm 3 (Liebschner et al., 2004) . Adult human bone has a secondary osteonal structure, i.e. osteons >100 µm containing blood vessels and with cement lines forming a boundary between adjacent lamellae (Wang et al., 1998) . Bone has the unique capacity to regenerate without the development of a fibrous scar, which is symptomatic of soft tissue healing of wounds. This is achieved through the complex interdependent stages of the healing process, which mimics the tightly regulated development of the skeleton (Kanczler and Oreffo, 2008) . monocyte-macrophage lineage, participate in the critical function of bone remodelling. The extracellular matrix is composed of collagenous proteins (predominantly collagen type I), non-collagenous proteins (osteocalcin, matrix gla protein, osteopontin and bone sialoprotein) and mineralized matrix (hydroxyapatite) (Kwan et al., 2008) . The cell responsible for bone formation, the osteoblast, is derived from a marrow stromal fibroblastic stem cell. These marrow stromal fibroblastic stem cells exist postnatally, are multipotent and have the ability to generate myelosupportive stroma, osteoblasts, adipocytes, chondrocytes, smooth muscle cells and astrocytes. This population of cells are also referred to as osteogenic stem cells, marrow stromal fibroblastic cells, bone marrow stromal stem cells, mesenchymal stem cells, stromal precursor cells and skeletal stem cells (Caplan, 1991; Bianco and Robey, 2001; Barry and Murphy, 2004) .
Development and formation of the skeleton (ossification) occurs by two distinct processes: intramembraneous and endochondral ossification. Both intramembraneous and endochondral bone ossification occur in close proximity to vascular ingrowth. Intramembraneous ossification is characterized by invasion of capillaries into the mesenchymal zone and the emergence and differentiation of mesenchymal cells into mature osteoblasts. These osteoblasts constitutively deposit bone matrix, leading to the formation of bone spicules. These spicules grow and develop, eventually fusing with other spicules to form trabeculae. As the trabeculae increase in size and number they become interconnected, forming woven bone (a disorganized weak structure with a high proportion of osteocytes), which eventually is replaced by more organized, stronger lamellar bone. This type of ossification occurs during embryonic development and is involved in the development of flat bones in the cranium, various facial bones, parts of the mandible and clavicle and the addition of new bone to the shafts of most other bones. In contrast, bones of load-bearing joints form by endochondral formation (Marks and Hermey, 1996) .
Regenerative medicine and stem cells
Regenerative medicine offers novel therapeutic approaches, not only to control the progression of diseases but also, for the first time, to promote repair through tissue regeneration, a complex process of events encompassing stem cell differentiation and tissue patterning with architectonic organization and functional restoration.
Cell-based bone tissue engineering is a rapidly evolving therapy option in bone reconstruction strategies. The discovery of stem and progenitor cells opened a new frontier in regenerative medicine, which aims to replace cells and tissues in a broad range of conditions associated with damaged cartilage, bone, muscle, tendon and ligament.
Stem cells are undifferentiated cells with the capability to regenerate tissues (Blau et al., 2001) . Adult stem cells are sparsely distributed in the body and perform functions such as, first, to produce identical copies of themselves for long periods of time, which is also referred to in the stem cell literature as the capacity for long-term self-renewal, and second, to engender transitional cell types before they reach the end of the differentiation cascade. The intermediate cell is defined as a progenitor or precursor cell, a cell that is regarded as committed to differentiate along a particular cellular pathway (Bruder and Fox et al., 1999; Caplan and Bruder, 2001 
Cell sources for bone regeneration
Cell sources for bone tissue engineering applications can be categorized with respect to their state of differentiation. With this idea, four different cell-based tissue engineering approaches have been described for the regeneration of bone. These strategies are based on the implantation of: (a) unfractionated fresh bone marrow; (b) purified, culture-expanded stem cells; (c) differentiated osteoblasts; or (d) cells that have been modified genetically to express rhBMP (Bruder and Fox et al., 1999) . In general, the less differentiated cells will be more easily expanded in vitro due to their high proliferation rate, while the differentiated cells will be more effective in vivo due to their higher and rapid production of mineralized extracellular matrix. For each type of cells use, advantages and disadvantages can be found.
Osteoblasts
Despite their lineage commitment to bone formation, osteoblasts derived from autologous bone represent a relatively limited source. In the early phase, the nonstem-cell approach was usually used to prove the concept of bone regeneration. For example, Vacanti et al. reported that bone tissue could be generated in the subcutaneous tissue of nude mice after implantation of degradable polymer seeded with osteoblasts isolated from periosteum (Vacanti et al., 1993; Vacanti and Upton, 1994) . Studies of animal model and human osteoblasts have described an attenuation of osteogenic differentiation and the proliferative response to mitogenic stimuli with aging (Zuk et al., 2001; Simonsen et al., 2002) . Friedenstein et al. (1968) found there were osteogenic precursor cells located in the bone marrow in a population of fibroblastic cells that could form a cell colony, named fibroblastic colony-forming units (CFUFs). The mammalian bone marrow (BM) is composed of different types of stem cells, among which are cells termed mesenchymal stromal cells or mesenchymal stem cells (MSCs) (Prockop, 1997; Blau et al., 2001) . Mesenchymal cells are originally defined as primordial cells of mesodermal origin, giving rise to cells such as adipocytes (Young et al., 1998; Pittenger et al., 1999; Endres et al., 2003) , osteoblasts (Pittenger et al., 1999; Donald et al., 1996; Jaiswal et al., 1997; Kadiyala et al., 1997; Nilsson et al., 1999) chondrocytes (Kadiyala et al., 1997; Pittenger et al., 1999; Johnstone et al., 1998; Mackay et al., 1998) , tenocytes (Awad et al., 1999) , skeletal myocytes (Pereira et al., 1995; Horwitz et al., 1999; Jiang et al., 2002; Bhabavati et al., 2004; Smith et al., 2004; Beyer and da Silva, 2006; Sethe et al., 2006) . MSCs can also differentiate into cells of ectodermal origin, such as neurons (Woodbury et al., 2000) , and of endodermal origin, such as hepatocytes (Petersen et al., 1999) .
Mesenchymal stem cells
Adult MSCs have also been isolated from muscles (Deasy et al., 2001) , peripheral blood (Kuznetsov et al., 2001; Roufosse et al., 2004) , fat (Lee RH et al., 2004) , hair follicles and scalp subcutaneous tissue (Shih et al., 2005) , periodontal ligament (Trubiani et al., 2005) , fetal bone marrow, blood, lung, liver and spleen (In't Anker et al., 2003) , as well as pre-natal tissues such as cord blood (Erices et al., 2000) and placenta (Fukuchi et al., 2004; In't Anker et al., 2004) . As a result, significant efforts have been directed at identifying postnatal sources for multipotent cells. Multipotent cells have been identified in bone marrow, adipose tissue, placenta, umbilical cord, human amniotic fluid, dental pulp and skeletal muscle among others (Freeman, 1997; Clarkson, 2001; Mitka, 2001; Kadner et al., 2002; Kaviani et al., 2002 Kaviani et al., , 2003 Rosser and Dunnett, 2003; Savitz et al., 2004) .
Currently, MSCs are isolated through a methodology based on gradient centrifugation and adherence to plastic culture surfaces, as described by Haynesworth and coworkers in the early 1990s (Haynesworth et al., 1992) . Compared to unfractionated bone marrow, mesenchymal stem cells generate greater bone formation in preclinical studies (Kahn et al., 1995; Inoue et al., 1997) . However, gradual loss of both their proliferative and differentiation potential has been observed during in vitro expansion (Mauney et al., 2005) .
The cells from unfractionated fresh bone marrow are relatively easy to collect but it will not be possible to use these cells in allotransplantation, as bone marrow contains T lymphocytes that encounter and respond to host antigens in virtually all tissues in the body, leading to multi-system graft-versus-host syndrome (Weissman et al., 2000) . Mesenchymal stem cells isolated from bone marrow aspirate, adult peripheral blood, neonatal cord blood or liver, for example, could present advantages from an immunological point of view (Javazon et al., 2004) . However, as one of every 100 000 nucleated cells derived from bone marrow is a stem cell, a procedure of isolation is required in order to decrease the volume of material injected (Connolly et al., 1989) .
MSCs express a complex pattern of molecules, including CD105 (SH2), CD73 (SH3 and SH4), CD106 (VCAM-1), CD54 (ICAM-1), CD44, CD90, CD29, STRO-1, as well as immune molecules such as HLA class I and II [the latter only upon the effect of interferon-γ (IFN-γ )] and CD119 (IFN-γ receptor). Haematopoietic markers, such as CD45 and CD34, are normally not expressed (Krampera et al., 2005 (Krampera et al., , 2006a . MSCs also express cytokines, growth factors, extracellular matrix and adhesion-related receptors (Ringe et al., 2002) .
Among all adult stem cells, bone marrow stem cells remain the most commonly used cell source for bone regeneration and repair in the studies using different animal models. On the basis of in vitro observation that MSCs can differentiate into osteocytes and chondrocytes, many attempts have been made to use expanded MSCs for in vivo tissue repair (Barry, 2001; Long, 2001; Fibbe, 2002) . Osteogenic induction is conducted by culturing human BMSCs in an induction medium containing the synthetic glucocorticoid dexamethasone, L-ascorbic acid, 1,25-dihydroxyvitamin D 3 and the organic phosphate β-glycerophosphate playing a role in the mineralization and modulation of osteoblast activities (Bellows et al., 1990; Chung et al., 1992; Tenenbaum et al., 1992; Liu et al., 1999) . After 16 days of culture, induced cells exhibited an osteogenic phenotype by alkaline phosphatase expression, reactivity with anti-osteogenic cell surface monoclonal antibodies, modulation of osteocalcin mRNA production and the formation of a mineralized extracellular matrix containing hydroxyapatite. The differentiation of MSCs into the osteogenic lineage is also stimulated by the addition of vitamin D 3 (Rickard et al., 1994; Jorgensen et al., 2004) . A similar inducing effect can also be achieved by using growth factors such as the bone morphogenetic protein (BMP) family (Hanada et al., 1997; Yeh et al., 2002; Gregory et al., 2005) , and if the cells are cultured on collagen (Yang et al., 2004; Salasznyk et al., 2004a; Salasznyk et al., 2004b) and calcium phosphates (Murphy et al., 2005; Salgado et al., 2005) . Mesenchymal progenitors derived from juvenile bone marrow have the potential to undergo multiple differentiation pathways. Although it has been suggested that osteoblasts and adipocytes share common precursors within the adult stromal system (Bennett et al., 1991) , human bone marrow-derived precursors showed no obvious differentiation into adipocytic cells, when stimulated with osteogenic medium supplemented with dexamethasone (Dex) in monolayers. In other studies, depending on the presence of Dex in primary or secondary cultures of marrow stromal cells, an inverse relationship between the differentiation of adipocytic and osteogenic cells in marrow stromal cells has been reported (Beresford et al., 1992) .
Bone marrow-derived MSCs have been seeded on extracellular matrices such as hydroxyapatite and then implanted in vivo into NOD/SCID mice, subsequently observing bone formation (Krebsbach et al., 1997) . In combination with scaffolds/matrices, it was possible for seeded MSCs to repair segmental defects of critical size in various animal models (Bruder et al., 1998; Kon et al., 2000; Petite et al., 2000; Arinzeh et al., 2003; Holy et al., 2003) . Similarly, bone marrow cells infused in children with osteogenesis imperfecta also increased, 3 months later, the mean number of osteoblasts, the formation of new lamellar bone and the total body mineral content. In addition, they eventually lowered the frequency of fractures and enhanced the body growth rate (Beyer and da Silva, 2006) . Other studies in animals showed that the best route of MSC administration to induce local repair or regeneration of bone, cartilage or tendon is the in situ injection or implant (Richards et al., 1999) . Particularly promising for orthopaedic applications, especially for bone formation, is the use of natural or synthetic biomaterials as carriers for MSCs delivery (Cancedda et al., 2003) . A number of clinical studies have shown the efficacy of this approach in humans. Porous ceramic scaffolds loaded with in vitro expanded autologous bone marrow-derived MSCs were successfully implanted in three patients with large bone defects (Quarto et al., 2001) . MSCs can also potentially be used to engineer cartilage-bone composites for the repair of defects extending from the articular surface into the underlying bone (Martin et al., 1998) .
Stem cells have recently evoked interest as a promising alternative cell source for treating articular cartilage defects, helped by the development of MSCbased strategies of tissue engineering to induce in situ differentiation of mesenchymal progenitors into cartilage Jorgensen et al., 2001) .
Autologous chondrocytes have a limited capacity to proliferate, on the other hand, MSCs are quickly amplified in monolayers. The easy availability of MSCs from various tissues, such as bone marrow, adipose tissue, synovial membrane and other tissues, together with their high proliferation capacity, make them attractive as a distinguished cell substitute for chondrocytes in cartilage regeneration (Friedenstein et al., 1970; Castro-Malaspina et al., 1980; De Bari et al., 2001; Noth et al., 2002; Baksh et al., 2004) .
MSCs have been used in vivo to repair full-thickness joint cartilage defects in animal models, using various carrier matrices (Wakitani et al., 1994; Caplan et al., 1997; Murphy et al., 2000; Adachi et al., 2002; ). Indrawattana and co-workers (2004) described the use of three different growth factors, TGFβ3, BMP-6 and IGF-1, in combination with pellet cultures of human bone marrow cells, for cell induction. Cells exhibited features of chondrocytes in their morphology and extracellular matrix, in both inducing patterns of combination and cycling induction. Expression of gene markers of chondrogenesis, collagen type II and aggrecan was noticeable. In rabbits, full repair of full-thickness defects of joint cartilage was observed after transplantation of autologous MSCs dispersed in a type I collagen gel, which was then transplanted into a large and full-thickness defect in the weight-bearing surface of the medial femoral condyle (Wakitani et al., 1994) . Twentyfour weeks after transplantation, the reparative tissue was stiffer and less compliant than the tissue derived from empty defects, but less stiff and more compliant than the normal cartilage. MSCs have been successfully used for intervertebral disc regeneration in a rat model, using local injection of fluorescently labelled MSCs (Crevensten et al., 2004) . After an initial decrease at 7 and 14 days after injection, fluorescent MSCs inside the disc returned to the initial number of injected cells at 28 days, with 100% cell viability. Autologous bone-marrow-derived MSCs have been applied to patients with osteoarthritis .
For in vitro chondrocyte differentiation, the most commonly used method in this field established over many years has involved culturing MSCs in chondrogenic medium as cell aggregates, often referred to as pellet culture, which was originally developed using rabbit MSCs and later with human bone marrow-derived stem cells (Yoo et al., 1998) . In 2007, this method was modified with a different format for the culture, employing a porous membrane support for the cells that initially creates a shallow multilayer of stem cells, which then differentiate and grow into a disc of cartilage-like tissue. This resulted in a more uniform differentiation of the MSCs and more efficient production of matrix by the cells (Murdoch et al., 2007) . Attempts to use these cells in the clinical setting have been restricted to implantation in human knees in a carrier gel Kuroda et al., 2007) . Human mesenchymal stem cells were cultured in vitro in a poly(DL-lactic-co-glycolic acid)-collagen biodegradable polymer scaffold in serum-free DMEM containing TGFβ3 . After 4 weeks, the matrices were positively stained by safranin O and toluidine blue, as well collagen type ll and proteoglycan were detected around the cells. Three-dimensional PLGA scaffolds seeded with cultured rabbit MSCs were also transplanted into large defects in rabbit knees and analysed histologically after the operation. A hyalinelike cartilage structure was shown at 12 weeks after the transplantation (Uematsu et al., 2005) . MSCs and chondrocytes embedded in a polylactid acid matrix placed into a full-thickness cartilage defect in rabbits showed a hyaline cartilage-like histology (Yan and Yu, 2007) . The histology scores in these groups were significantly higher than in groups where the defect was filled with fibroblasts or without cells. Studies demonstrated that mechanical stress strongly improves cartilage regeneration through the maintenance of hyaline cartilage, and that cyclic mechanical compression enhances the expression of chondrogenic markers in mesenchymal progenitor cells differentiated in vitro, resulting in increased cartilaginous matrix formation (Guilak et al., 2004; Schumann et al., 2006; Mauck et al., 2007) .
Adipose-derived stem cells
Isolated adipose stem cells (ASCs) acquire a fibroblast-like morphology, similar to that observed for MSCs, and have been shown to have potential for osteogenic, adipogenic, chondrogenic and other lineage differentiation (Huang et al., 2000; Zuk et al., 2002; Gimble, 2003; Gimble and Guilak, 2003a; Awad et al., 2004; Dragoo et al., 2004; Hicok et al., 2004; Rodriguez et al., 2005; Betre et al., 2006) . Osteogenic differentiation can be assessed by the identification of osteoblast phenotype markers, such as ALP activity, extracellular matrix production by the presence of bone matrix proteins such as osteopontin, osteonectin, bone sialoprotein-2, osteocalcin and collagen type I, among others, and by the calcification and formation of bone nodules (Gimble and Guilak, 2003b) .
Chondrogenic differentiation can be verified by the presence of chondrocyte phenotypic markers, such as aggrecan, collagen type lI, Sox-9, collagen type 6, collagen type 10 and collagen type 9. A study has shown that ASCs have the same ability as bone marrow MSCs to regenerate bone and repair bone defects in vivo (Cowan et al., 2004) . Significant osteogenic formation and defect bridging was evident after 2-12 weeks, respectively, following a critical-sized mouse calvarial bone defect. Clonal populations within ASCs are multipotent and possess the potential for differentiation along adipose, chondrogenic and osteogenic lineages. The ability of mouse ASCs to regenerate bone in a critical-sized calvarial defect model was demonstrated. ASCs were seeded on to apatite-coated poly(DL-lactic-co-glycolic acid) (PLGA) scaffolds and implanted into 4 mm parietal bone defects of adult mice (Kwan et al., 2008) . Radiographical analysis of calvarial healing revealed that mice treated with ASCs had greater bone regeneration than mice treated with osteoblasts at the 4 week time point.
The potential of these cells to be used for bone tissue engineering was shown by Hicok et al. (2004) , who demonstrated the ability of ASCs to form bone in vivo. When seeded on hydroxyapatite/tricalcium phosphate subcutaneously implanted into SCID mice for 6 weeks, ASCs were shown to be capable of causing the formation of human osteoids in 80% of the implant. Hennig et al. (2007) demonstrated that adipose tissue-derived MSCs reveal an altered bone morphogenic protein (BMP) profile compared to MSCs from bone marrow and required exogenous application of BMP, in addition to TGFβ, to compensate for the reduced endogenous expression of BMP2, −4 and −6. Application of BMP6 in combination with TGFβ completely eliminated the reduced chondrogenic differentiation potential of MSCs derived from adipose tissue. This demonstrated that MSCs isolated from different tissues do not represent identical cell populations, but vary in the expression profile of some growth factors relevant for chondrogenesis.
Embryonic stem cells
Embryonic stem cells (ESCs) are harvested from the inner cell mass of the blastocyst and are acclaimed for their unlimited capacity for self-renewal (Allison et al., 2002; Preston et al., 2003) . They were primarily isolated during early 1980s from mouse embryos (Evans and Kaufman, 1981; Martin, 1981) , then later from human embryos (Thomson et al., 1998; Reubinoff et al., 2000) . Human ESCs are pluripotent, as they can give rise to essentially all cell types in the body (Buckwalter et al., 1997; Hentthorn, 2002) . In vitro and in vivo experiments have demonstrated the ability of ESCs for osteogenic differentiation (Whang and Lieberman, 2003) . In spite of this broad differentiation capability and potential to be used in regenerative medicine, the predisposition of these cells for teratoma formation and the political and ethical debate currently surrounding their use pose substantial challenges for forward progress on these cells (Lauffenburger and Schaffer, 1999; Montjovent et al., 2004) .
Multipotent periosteum cells
The periosteum is a bilayered tissue membrane that is attached to bone cortex (Taylor, 1992) . A number of studies (Nakahara et al., 1990; Nakata et al., 1992; Fang and Hall, 1996; O'Driscoll et al., 2001) have also shown that the periosteum cambium layer also possesses chondroprogenitor cells that can also promote new cartilage. Perka et al. (2000) reported that multipotent cells isolated from the periosteum were seeded on PLGA scaffolds and placed in critical-sized defects in the metadiaphyseal ulnas of New Zealand white rabbits. After 28 days, the constructs had bone formation and adequate transplant integration at the margins to the surrounding bone tissue. Vacanti et al. (2001) reported the replacements of an avulsed phalanx with lamellar bone, coral, blood vessels and soft tissue. Shantz et al. (2002) reported on the in vivo endochondral bone formation with osteoid production detectable through Von Kossa and osteocalcin staininq after 6 and 17 weeks. Schmelzeisen et al. (2003) showed that MPCs give rise to viable osteocytes in trabecular bone.
MPCs have also been used in cartilage tissue engineering. Stevens et al. (2004a) used a rapidcuring alginate gel system to support periosteum-derived chondrogenesis. After 6 weeks of culture, significant quantities (>50%) of the total area of the periosteal explants were composed of cartilage that was hyalinealginate or agarose-based gels, significantly enhanced cell proliferation, resulting in increased neocartilage formation at later stages (Stevens et al., 2004b) .
Skeletal muscle-derived stem cells
Two muscle stem cell populations with a possible mesenchymal character have been described: satellite cells (SCs) and muscle-derived stem cells (MDSCs).
Muscle satellite cells are found adjacent to skeletal muscle myofibres and lie underneath the basal lamina. When initiating division, satellite cells express either myf-5 or Myo-D (O'Brien et al., 2002) . Furthermore, this cell population has also shown to express a number of other proteins, including desmin, c-met, M-cadherin, PaxT and Bcl-2. Satellite cells have for long been considered as precursor rather than stem cells. Studies reported that from SCs and upon stimulation with BMPs, it was possible for these cells to differentiate into osteogenic lineage expressing both alkaline phosphatase (ALP) and osteocalcin (Asakura et al., 2001; Wada et al., 2002) .
Muscle-derived stem cells (MDSCs) are believed to be located either in the connective tissue regions of the skeletal muscle or in the capillaries surrounding the myofibres (Lee et al., 2000; Qu-Petersen et al., 2002; Peng and Huard, 2004) . In culture, MDSCs express desmin and Myo D and stem cell markers such as CD34, sca-1 and Bcl-2 (Torrente et al., 2001; Cao and Huard, 2004) . McKirmey-Freeman et al. (2002) and Adachi et al. (2002) showed that CD45-MDSCs have both chondrogenic and osteogenic potential. Other studies described positive results regarding the regeneration of critical-sized bone defects (Qu et al., 1998; Peng et al., 2001; Lee JY et al., 2002; Wright et al., 2002) .
Prenatal stem cells
Several sources for adult stem cells with putative mesenchymal character have been described from prenatal tissues and fluid, and these include cord blood, amniotic fluid, umbilical vein and Wharton's jelly (Erices et al., 2000; Rosada et al., 2003; Gang et al., 2004; Kogler et al., 2004; Lee OK et al., 2004; Tondreau et al., 2005) .
In cord blood, Erices et al. (2000) reported the presence of a population of mesenchymal progenitors that expressed several MSC-related antigens, such as SH2, SH3, SH4, ASMA, MAB 1470, CD13, CD29 and CD49e. These cells could be directed toward the osteogenic lineage, showing bone nodule formation and ALP activity. clonally expanded adult stem cells derived from umbilical cord blood with a mesenchymal character, which were able to differentiate into several lineages, including osteogenic and chondrogenic lineages. Rosada et al. (2003) subcutaneously implanted immunocompromised mouse cord blood MSCs that had previously been mixed with hydroxyapatite/tricalcium phosphate powder. After 8 weeks, It was possible to observe the presence of bone at the interface of the HA/TCP powder and the surrounding tissues. Kogler et al. (2004) implanted in mice, either subcutaneously or in femoral defects, a three-dimensional (3D) scaffold seeded with cord blood MSCs. After 3 weeks, a cartilage tissue-like formation was observed in the subcutaneous model and after 12 weeks bony reconstitution was observed.
Amniotic fluid is known to contain multiple cell types derived from the developing fetus (Priest et al., 1978; Polgar et al., 1989 ). De Coppi et al. (2007 showed that cKit-expressing cells within this heterogeneous population can give rise to differentiated cells of bone lineage. Human amniotic fluid stem cells (AFSCs) of the same clone can be induced to express markers characteristic of osteocytes, such as Runx2, osteocalcin and alkaline phosphatase. Calcium deposition was shown in human AFS cells maintained in osteogenic differentiation medium in vitro by measuring calcium-cresolophthalein complex levels. Von Kossa staining of AFS cells in alginate/collagen scaffold recovered 8 weeks after implantation indicated strong mineralization. The formation of tissue-engineered bone from printed constructs of osteogenically differentiated human AFS cells in immune-deficient mice was measured using micro-CT scan of mouse 18 weeks after implantation of printed constructs. At sites of implantation of the scaffolds containing AFS cells, blocks of bone-like material were observed with a density somewhat greater than that of mouse femoral bone. Control scaffolds lacking AFSCs did not promote the formation of bony tissue.
The umbilical cord vein was shown by Romanov et al. (2003) to possess mesenchymal progenitors that showed alkaline phosphatase activity. According to Kim et al. (2004) , it was possible to obtain these MSC-like cells from only 6% of the cords. Fibroblastic cells were negative for endothelial markers such as Von Willenbranf factor (vWF) and PECAM-1. As in other cases, when exposed to osteogenic conditions these cells revealed typical signs of osteogenic differentiation through the deposition of a mineralized extracellular matrix and cells expression of Runx2 and osteopontin.
In Wharton's jelly, the primitive connective tissue of the umbilical cord, Sarugaser et al. (2004) described a cell population designated human umbilical cord perivascular cells (HUCPVCs). Upon culture, these cells displayed a fibroblast-like morphology, expressing at the same time α-actin, desmin, vimentin, 3G5 and typical MSC markers such as SH2, SH3 and CDl44, and a colony-forming unit fibroblast frequency (CFU-F) of 1 : 333. These HUCPVCs had a subpopulation that exhibited osteogenic phenotype and elaborated bone nodules. Wang et al. (2004) showed that, upon stimulation of cells positive for SH2 and SH3 with osteogenic supplements, it was possible to observe a cell population with high indices of ALP activity as well as the expression of osteopontin. This cell population were also shown to possess chondrogenic potential, expressing collagen ll.
Genetically modified cells
The transfection of the cells can be done either in two steps with an in vitro transfection followed by injection of the modified cells (a procedure called 'ex vivo gene therapy') or in one step by transfecting the cells directly in the body (a procedure called 'in vivo gene therapy'). Cells genetically modified to express bone formation cytokines could be used to take advantage of genetic therapy (Lauffenburger and Schaffer, 1999) . BMPs have promising potential for clinical bone and cartilage repair, working as bone-inducing components in diverse tissueengineering products. Current clinical uses include spinal fusion, healing of long bone defects and craniofacial and periodontal applications, among others (Bessa et al., 2008) . Combining gene therapy and tissue-engineering methodologies to enhance tissue regeneration, cells overexpressing BMP have been developed and used in animal studies (Gazit et al., 1999) . Gene transfection of osteogenesis-related transcription factors such as Osterix (Tu et al., 2006) and Runx2 (Byers et al., 2004) has been shown to induce an osteogenic phenotype of BMSCs.
Human skin fibroblasts
The Yamanaka and Thompson groups demonstrated that the ectopic expression of a select group of genes can enable postnatal, human fibroblasts and other somatic cells to exhibit many of the hallmarks of human embryonic stem cells (Park et al., 2003; Hohlfeld et al., 2005 , Takahashi et al., 2007 . These findings are especially important, as they demonstrate the potential for reprogramming postnatal somatic cells to a pluripotent state (Wernig et al., 2007) . These studies provide a promising direction for generating patient-, tissue-and disease-specific stem cells, presumably without immunological rejection concerns. Given the abundance and ease with which skin fibroblasts can be harvested autogenously, such an approach may provide patients with specific cell types needed for tissue/organ regeneration, including bone and cartilage.
Future directions
The presented stem cell populations have shown promising results, key characteristics and differentiation potential to be used for bone and cartilage tissue regeneration. The amazement starts when reviewers (Krampera et al., 2006b; Pioletti et al., 2006; Salgado et al., 2006; Mano and Reis, 2007) start to gaze at the number of these populations, how their diversity might have arisen and when one considers the evolutionary processes behind this difference. This inextricably drove researchers to closely examine processes responsible for cell differentiation into bone and cartilage, scrutinizing matrix sources nature has readily provided for millions of years (Cruz et al., 2008; Gomes et al., 2008; Oliveira et al., 2008) . Most experiments with bone and cartilage tissue engineering have been carried out with small animals or small-sized defects. However, human defects are normally larger and more complicated, thus requiring larger repair tissues and structural and mechanical properties similar to human normal tissues. In the coming years, further clinical trials involving stem and progenitor cells have the potential to deepen our knowledge of stem cell biology and dramatically improve their application for tissue regeneration. It specifically remains necessary to investigate further the different signalling pathways involved in the proliferation and differentiation of stem cells and the further identification of related markers for these cells, so that functional stem cells can be obtained. It is our belief that the isolation and use of SCs with proper electrical, physical and chemical maturity for tissue engineering is an essential factor. If donor SCs are engrafted in order to support the strength and tensile capacity of compromised bone or skin, functional electrical cell coupling should first be satisfied. In contrast to host osteoblasts, stem cell-differentiated osteoblasts might be lacking a proper functional coupling, thereby creating a heterogeneous focus upon implantation. To optimally support a compromised tissue upon engraftment, donor cells should preferably be similar to, and integrate mechanically and electrically with, the host tissue (van Veen et al., 2006) . If not, implantation of cells will not only chronically fail to increase the strength/tensile capacity of that tissue but, even more deleterious, disturb the repartition of forces applied to regenerated tissue. The ex vivo formation of complex 3D hybrid tissues (i.e. joint cartilage with subchondral bone and integrated vascular access for implantation) may also revolutionize the treatment of damaged skeletal tissue. Further developments in these areas of stem cell research will have a significant impact on functional bone and cartilage regeneration and open a novel avenue for regenerative medicine.
